Enovid Product FAQ

Enovid was developed by a joint Israel/Canadian research company that specializes in the application of nitric oxide for therapeutic use. Enovid gained world-wide popularity and demand as a front-line defence during all the years of the COVID-19 pandemic. In 2024, the manufacturers of Enovid changed the name of the product to NOWONDER™. Other than that, the two products are exactly the sam

NOWONDER™ releases nitric oxide (NO), a compound with documented antiviral effects. Nitric oxide disrupts viral replication by modifying viral proteins and RNA. In vitro studies show NO inhibits SARS-CoV-2 replication effectively and field testing backs this up with hard evidence of how it can reduce viral loads.

No, because vaccines and nasal sprays work in different but complementary ways. Vaccines train the immune system over time, building memory and adaptive immunity. Nasal sprays are meant to offer short-term, localized defense, an umbrella in a viral downpour.

A phase 2 trial in 2021 showed that in patients with early COVID-19, the spray could reduce viral load by more than 95% within 24 hours and 99% within 72 hours. Another real-world study in Thailand suggested fewer symptomatic infections among high-risk users compared to placebo.

Viruses like the SARS-CoV-2 that causes COVID-19 infections are master shapeshifters. Subvariants, particularly XBB and FLiRT strains, have shown higher transmissibility and immune evasion. The good news is that nitric oxide doesn’t depend on spike protein shape, meaning it can reduce viral load even as the virus mutates. That makes it potentially more variant-agnostic than spike-targeting antibodies or vaccines.

Nasal sprays are designed to reduce viral load or transmission risk, but they don’t build long-term immunity. Vaccines train the immune system to recognize and fight the virus even if exposure happens later. The take-away lesson is to use sprays in addition to, not instead of, vaccination.

NOWONDER™ is formulated to deliver measured doses of nitric oxide with each spray, and this appears to be well tolerated in trials. As long as the product guidance is followed, NOWONDER™’s safety level is high. If there are any questions, talk to a healthcare provider or pharmacist.

Enovid was developed by a joint Israel/Canadian research company that specializes in the application of nitric oxide for therapeutic use. Enovid gained world-wide popularity and demand as a front-line defence during all the years of the COVID-19 pandemic. In 2024, the manufacturers of Enovid changed the name of the product to NOWONDER™. Other than that, the two products are exactly the sam

Yes. Studies show that early use of nitric oxide sprays in infected individuals can reduce viral load in nasal secretions, which could translate into lower transmission.

NOWONDER™ has an excellent safety record, thanks to the closely controlled dose of nitric oxide delivered with each spray. As long as the instructions that come with each box are followed, there is a minimal risk of serious side effects. In rare cases, people have experienced headaches, nosebleeds, or persistent nasal burning sensations, and are advised to discontinue using the product immediately. If these symptoms persist, they should consult a healthcare provider.

NOWONDER™ Nitric Oxide Spray has earned the most clinical buzz, with multiple trials suggesting it would reduce viral load and result in fewer symptomatic infections. No other nasal spray comes close to both professional endorsement and popularity worldwide.